Stocktoria
ARS Pharmaceuticals, Inc. SPRY
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-12-04
ARS Pharmaceuticals, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -212.9% | -3.5% | -225066.7% | -2698.8% | -353.3% |
| Net margin | -203.3% | 9.0% | -181216.7% | -2635.4% | -367.7% |
| FCF margin | -203.1% | 14.6% | -198136.7% | -3060.6% | -319.9% |
| Return on assets | -52.3% | 2.3% | -23.3% | -12.3% | -32.9% |
| Return on equity | -149.9% | 3.1% | -23.6% | -12.7% | 64.7% |
| Debt / equity | 0.84× | 0.00× | — | — | — |
| Current ratio | 7.28 | 14.26 | 96.92 | 51.01 | 7.42 |
| Revenue growth | -5.5% | 297063.3% | -97.7% | -76.1% | — |
Source: SEC EDGAR filings · CIK 0001671858 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.